Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amy DuPage"'
Autor:
Shweta Singh, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, Leyu Wang, Michael Krimm, Ken Wong, Jason Sagert, Kimberly Tipton, Stephen J. Moore, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Shouchun Liu, Olga Vasiljeva, Yingchun Li, Tracy Henriques, Ilaria Badagnani, Shawn Jeffries, Siew Schleyer, Rob Leanna, Claus Krebber, Sridhar Viswanathan, Luc Desnoyers, Jonathan Terrett, Marcia Belvin, Susan Morgan-Lappe, W. Michael Kavanaugh, Jennifer Richardson
Publikováno v:
Molecular Cancer Therapeutics. 21:1326-1336
Probody therapeutics (Pb-Txs) are conditionally activated antibody–drug conjugates (ADCs) designed to remain inactive until proteolytically activated in the tumor microenvironment, enabling safer targeting of antigens expressed in both tumor and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb073726d937f7e11b7d94e91eed5013
https://doi.org/10.1158/1535-7163.mct-21-0193
https://doi.org/10.1158/1535-7163.mct-21-0193
Autor:
Jennifer Richardson, W. Michael Kavanaugh, Susan Morgan-Lappe, Marcia Belvin, Jonathan Terrett, Luc Desnoyers, Sridhar Viswanathan, Claus Krebber, Rob Leanna, Siew Schleyer, Shawn Jeffries, Ilaria Badagnani, Tracy Henriques, Yingchun Li, Olga Vasiljeva, Shouchun Liu, Shanti Duvur, Sarah Patrick, Adam Miller, Eric Ureno, Andrew Jang, Yuanhui Huang, Stephen J. Moore, Kimberly Tipton, Jason Sagert, Ken Wong, Michael Krimm, Leyu Wang, Fritz Buchanan, Matthew Ravn, Niharika Chauhan, Kristi Elkins, Amy DuPage, Laura Serwer, Shweta Singh
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734c4baf0734abf8c7e252b8e10c6fd0
https://doi.org/10.1158/1535-7163.22523304.v1
https://doi.org/10.1158/1535-7163.22523304.v1
Autor:
Yuanhui Huang, Shouchun Liu, Adam Miller, Serwer Laura Patterson, Jennifer Richardson, Matthew M. Ravn, Shweta Singh, Michael Krimm, Michael P. Kavanaugh, Niharika Chauhan, Badagnani Ilaria, Andrew Jang, Rob Leanna, Ken Wong, Sarah Patrick, Claus M. Krebber, Henriques Tracy, Fritz G. Buchanan, Sridhar Viswanathan, Shanti Duvur, Eric Ureno, Amy DuPage, Susan Morgan-Lappe
Publikováno v:
Molecular Cancer Therapeutics. 17:B116-B116
ProbodyTM therapeutics are antibody prodrugs designed to remain largely inactive until proteolytically activated in the tumor microenvironment (TME), potentially enabling the safer targeting of antigens that are highly expressed in both tumor and nor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a45c41479baf9927bb2e03c3e55d52c3
https://doi.org/10.1158/1535-7163.targ-17-b116
https://doi.org/10.1158/1535-7163.targ-17-b116
Autor:
Luc Desnoyers, Yuanhui Huang, Shouchun Liu, Annie Yang Weaver, Shweta Singh, Linnea Diep, Kim Tipton, Jonathan Alexander Terrett, Clayton White, Jennifer Richardson, Amy DuPage, W. Michael Kavanaugh, Michael Krimm, Jason Gary Sagert
Publikováno v:
Cancer Research. 76:2975-2975
The targets of Antibody Drug Conjugates (ADCs) have typically been selected by identifying transmembrane antigens that are highly expressed in tumors but are low or absent in normal tissues. The number of potential ADC targets meeting these requireme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a77330f2b46f55a1d1e023052ceb462
https://doi.org/10.1158/1538-7445.am2016-2975
https://doi.org/10.1158/1538-7445.am2016-2975
Autor:
Luc Desnoyers, Yuanhui Huang, Andrew Jang, Elizabeth Menendez, Jason Gary Sagert, Shouchun Liu, Eric Brecht, Olga Vasiljeva, Margaret Nguyen, Nicole Lapuyade, James W. West, Michael Krimm, Annie Yang Weaver, Jeanne Grace Flandez, Stephen R. Moore, Judi Ford, W. Michael Kavanaugh, Linnea Diep, Tereza Sputova, Jonathan A. Terrett, Shweta Singh, Amy DuPage, Jennifer Richardson
Publikováno v:
Molecular Cancer Therapeutics. 14:C165-C165
Antibody drug conjugates (ADCs) have shown their greatest clinical utility when targeting antigens expressed at very high levels on cancer cells that have coincidentally lower expression in normal tissues. This is exemplified by the approvals of tras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dfa74c2d7feb91893fa08e253ae6595
https://doi.org/10.1158/1535-7163.targ-15-c165
https://doi.org/10.1158/1535-7163.targ-15-c165